Corporate Developments at Hofseth BioCare ASA

Subsequent Offering and Shareholder Update

On 21 November 2025, Hofseth BioCare ASA (HBC) completed a subsequent offering.

  • Primary insider participation: Christoph Baldegger, a board member, subscribed for 368 320 offer shares. After the transaction, Baldegger will hold 3 616 296 shares, representing approximately 0.92 % of the total outstanding A‑shares with voting rights.
  • Subscription period: The last day for subscription to the offering was 20 November 2025, as announced in two separate releases on 20 November and 21 November.

Extraordinary General Meeting

On 20 November 2025, HBC held an Extraordinary General Meeting (EGM).

  • All proposals presented in the notice issued on 30 October 2025 were resolved as presented.
  • Minutes from the meeting are attached to the announcement. The CEO, Jon Olav Ødegård, is available for further information.

Strategic Product Partnership

On 20 November 2025, HBC announced a strategic partnership with Metabolic Elite, guided by nutrition expert Jim LaValle.

  • The collaboration will combine HBC’s validated marine‑based ingredients—including ProGo® bioactive peptides—with Metabolic Elite’s performance formulations.
  • The partnership aims to develop new products that leverage HBC’s sustainable marine nutrition expertise.

Financial Position

As of 19 November 2025, the closing price of HBC’s shares was 1.70 NOK.

  • The company’s market capitalization is 883 040 000 NOK.
  • The 52‑week high and low were 3.60 NOK and 1.16 NOK respectively, indicating a recent decline in share price.
  • The price‑earnings ratio is negative at –5.55, reflecting current profitability constraints.

Business Focus

HBC, headquartered in Ålesund, Norway, develops value‑added biomarine ingredients for human and pet consumption. Key products include:

  • OmeGo: salmon oil supplement.
  • ProGo: salmon protein hydrolysate powder used as a fast‑absorbing protein supplement.
  • CalGo: marine calcium powder derived from salmon bones, aimed at enhancing bone density in older individuals.

The company continues to expand its product portfolio through strategic alliances and market‑driven innovation, while maintaining a focus on sustainability and nutritional efficacy.